Targovax announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange.
The company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange.
“This move marks another exciting step for Targovax. Being part of the main market is an important development for the future of the company, giving us access to a larger investor base and helping enhance our visibility. We are pleased to have had the support from the Axess market and are delighted to have been accepted on to the Oslo main market,” said Øystein Soug, Chief Executive Officer of Targovax.
Since listing the shares of Targovax on Oslo Axess in July 2016, the company has achieved several milestones. For example they have presented encouraging top line two-year survival data from the TG01 clinical trial in resected pancreatic cancer patients. They have presented data showed a survival rate of 68% from the first patient cohort compared to published historical rate of 30-53%, suggesting a signal of clinical efficacy for the drug candidate. They have also been granted European patent for ONCOS-102, protecting Targovax’s ONCOS platform lead product until 2029 and strengthened its team with the appointment of Øystein Soug as Chief Executive Officer and the appointment of Erik Digman Wiklund as Chief Financial Officer.